Navigation Links
Angioplasty No Better Than Drug Treatment in Long Run

Benefit disappears within three years, study finds

WEDNESDAY, Aug. 13 (HealthDay News) -- There are some advantages to artery-opening angioplasty over drug treatment for people with heart disease, but those advantages disappear within three years, according to the latest report on a pivotal study on the subject.

Angioplasty does offer a higher quality of life for months to a couple of years, said study leader Dr. William S. Weintraub, chief of cardiology at the Christiana Health Care System in Delaware.

In the COURAGE trial, the researchers tested angioplasty, with stent implants, against drug treatment for 2,287 people with stable coronary disease. Earlier analysis found improved quality of life for those having the artery-opening procedure that is formally called percutaneous coronary intervention (PCI). The latest report, in the Aug. 14 issue of the New England Journal of Medicine, found that by 36 months, there was no significant difference in health status between the two treatment groups.

"What one can say is that for people with chronic, stable coronary disease, PCI can be deferred," Weintraub said. "They can continue on medication aimed at their specific risk factors -- hypertension, lipid disorders, diabetes -- and should be encouraged to have a good lifestyle, with exercise, smoking cessation and weight control."

A decision to have PCI can depend on how an individual feels, Weintraub said. "If people say, 'My pain is so bad I can't function,' that is one thing," he said. "If people say, 'I have angina, but I'm doing OK,' that's another."

Angina is the chest pain that is a chief symptom of coronary disease.

Cost could be a factor in some decisions, Weintraub said. PCI is more expensive than drug therapy, but the current report does not mention money. An economic analysis of the COURAGE alternatives was expected to be published in September, Weintraub said.

However, a preliminary cost-benefit analysis presented by Weintraub last November found that "PCI adds about $10,000, without any significant gain in years of survival or quality of life." The cost of one year of life added by PCI varies from $150,000 to $300,000, the analysis found.

The cost of PCI versus drug treatment must be considered "by society as a whole," he said. "But when a doctor talks to a patient, the doctor is an advocate for that patient."

An individual's health insurance status can matter, Weintraub acknowledged. "Paying the cost out of pocket gives one a different point of view," he said.

The attitude of medical insurance providers does matter, said Dr. Eric D. Peterson, a professor of medicine at the Duke Clinical Research Institute. Insurance companies now are quite willing to pay for PCI, and "until that category is changed, the effect of this study will be modest," he said.

The COURAGE results show that PCI should not be the treatment of choice for people with stable heart disease, Peterson said.

"We have justified angioplasty for years by saying it is of great benefit to patients," he said. "This study shows no survival benefit and shows that the benefit in regard to symptom relief is temporary. Medical therapy should be considered for all patients with stable angina, unless they have severe pain when diagnosed."

The fact that 21 percent of those in the COURAGE trial who started on drug treatment eventually had PCI shows that a decision on surgery can safely be delayed, he said.

The hazards as well as the benefits of PCI should be considered when a decision is made, Peterson said. Of 1,000 persons undergoing PCI, two will die, 28 will have heart attacks related to the procedure, 60 to 90 will have improved symptom relief, and 800 will have no noticeable benefit above that given by drug treatment, his editorial said.

Another paper in the same issue of the journal reported a trial testing a new clot-preventing drug, bivalirudin, against heparin, the standard treatment, in PCI. The study of 4,570 persons having PCI found that bivalirudin did not provide a net clinical benefit, said a group headed by physicians in Germany.

More information

Angioplasty is explained by the U.S. National Heart, Lung, and Blood Institute.

SOURCES: William S. Weintraub, M.D., chief, cardiology, Christiana Health Care System, Newark, Del.; Eric D. Peterson, M.D., professor, medicine, Duke Clinical Research Unit, Durham, N.C.; Aug. 14, 2008, New England Journal of Medicine

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
2. Off-Hours Heart Patients Less Likely to Get Angioplasty
3. State Report Ranks LIJ as New Yorks Best Hospital for Angioplasty Survival
4. Angioplasty Proves Reasonable Alternative to Bypass Surgery
5. Anticoagulant Drugs Had Similar Outcomes After Angioplasty
6. Comparison of anticoagulants for angioplasty show similar outcomes
7. The Elderly Can Be Candidates for Angioplasty, Stenting
8. Doing Angioplasty Long After Heart Attack Still Worth It, Analysis Shows
9. Delayed angioplasty -- big bucks, no bang
10. Are women at greater risk from angioplasty?
11. Angioplasty Equals Bypass Surgery for Heart Patients: Study
Post Your Comments:
Related Image:
Angioplasty No Better Than Drug Treatment in Long Run
(Date:11/27/2015)... , ... November 27, 2015 , ... According to an ... not changing the way that they are handling security in light of the recent ... security presence in an attempt to stop an attack from reaching U.S. soil. Especially ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced ... User Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics ... software users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they ... to buy during the Black Friday and Cyber Monday massage chair sales ... the Internet high and low to find the best massage chair deals, they can ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Therapeutic Drug Monitoring ... Forecasts, Competitive Intelligence, Emerging Opportunities"  report ... ) has announced the addition ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
Breaking Medicine Technology: